 |
市場調查報告書
商品編碼
1535724
抗球蟲藥物市場 - 按藥物類別（合成化合物、聚醚抗生素或離子載體）、藥物作用（抑制球蟲、殺球蟲）、動物類型（伴侶、牲畜）、配銷通路、全球預測（2024 - 2032 ）Anticoccidial Drugs Market - By Drug Class (Synthetic Compounds, Polyether Antibiotics or Ionophores), Drug Action (Coccidiostatic, Coccidiocidal), Animal Type (Companion, Livestock), Distribution Channel, Global Forecast (2024 - 2032) |
||||||
在動物健康意識不斷提高以及轉向天然和替代解決方案的推動下，全球抗球蟲藥物市場在 2024 年至 2032 年間將實現 4.1% 的複合年成長率。隨著消費者和生產者越來越重視動物福利，對有效的非抗生素治療的需求不斷成長。這一趨勢促進了天然抗球蟲藥物的開發和採用，從而提供更安全、更永續的疾病管理。專注於增強動物健康，同時最大限度地減少抗生素的使用，以滿足不斷變化的市場需求，從而促進行業的顯著成長。
例如，2022 年 4 月，Amlan International 為牲畜和家禽推出了兩種新的天然抗生素替代品：Phylox(R) Feed 和 NeutraPath(R)。這些產品無需使用抗生素即可增強腸道健康並提高生產經濟效益。這些新產品可增強腸道健康和生產效益，可能透過推廣天然解決方案並可能擴大畜禽管理選擇來影響市場動態。
抗球蟲藥物產業根據藥物類別、藥物作用、動物類型、配銷通路和地區而分散。
到 2032 年，殺球蟲領域將大幅成長，因為它能有效殺死球蟲寄生蟲並防止球蟲病的傳播。這些藥物在管理和控制牲畜、家禽和其他動物的感染方面發揮著至關重要的作用，有助於維持生產力並減少經濟損失。殺球蟲藥物在治療現有感染和預防新疫情方面的高效性推動了其在該行業中的主導地位，因為它們對於確保動物健康和最佳化農業產量至關重要。
由於畜牧業對有效疾病管理的迫切需求，到 2032 年，畜牧業將取得顯著進展。抗球蟲藥物對於預防和治療球蟲病至關重要，球蟲病是一種影響牲畜並可能導致重大經濟損失的寄生蟲感染。隨著對肉類和乳製品的需求增加，農民和生產者越來越依賴這些藥物來維持動物健康和生產力。對改善牲畜福利和減少疾病爆發的關注支撐了該領域的主導地位。
由於嚴格的監管標準、先進的獸醫實踐和較高的畜牧生產水平，歐洲抗球蟲藥物市場到 2032 年將保持適度的複合年成長率。該地區致力於維持嚴格的動物健康方案和預防疾病爆發，這推動了對有效抗球蟲解決方案的需求。此外，歐洲致力於整合創新療法並確保高品質的動物護理，這也為其帶來了巨大的市場佔有率。監管支持、行業標準和技術進步的結合使歐洲成為全球抗球蟲藥物行業的顯著貢獻者。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 球蟲病發生率增加
- 不斷成長的牲畜數量
- 對動物性蛋白質的需求不斷成長
- 產業陷阱與挑戰
- 藥物研發成本高
- 嚴格的監管要求
- 成長動力
- 成長潛力分析
- 監管環境
- 技術景觀
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年
- 主要趨勢
- 合成化合物
- 聚醚抗生素或離子載體
第 6 章：市場估計與預測：按藥物行動，2021 - 2032 年
- 主要趨勢
- 抑制球蟲
- 殺球蟲劑
第 7 章：市場估計與預測：按動物類型，2021 - 2032
- 主要趨勢
- 伴侶動物
- 狗
- 貓
- 其他伴侶動物
- 畜牧動物
- 牛
- 家禽
- 其他家畜動物
第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年
- 主要趨勢
- 獸醫醫院和藥房
- 零售藥局
- 其他分銷管道
第 9 章：市場估計與預測：按地區分類，2021 - 2032 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 10 章：公司簡介
- Bayer AG
- Boehringer Ingelheim International GmbH
- Ceva
- Cronus Pharma LLC
- Elanco Animal Health Incorporated
- Huvepharma EOOD
- Impextraco NV
- Merck & Co., Inc.
- Phibro Animal Health Corporation
- Vetoquinol SA
- Virbac SA
- Zoetis Inc.
Global Anticoccidial Drugs Market will achieve a 4.1% CAGR between 2024 and 2032, driven by rising awareness of animal health and a shift towards natural and alternative solutions. As consumers and producers increasingly prioritize animal welfare, there is a growing demand for effective, non-antibiotic treatments. This trend promotes the development and adoption of natural anticoccidial options that offer safer and more sustainable disease management. The focus on enhancing animal health while minimizing antibiotic use aligns with evolving market needs, contributing to significant industry growth.
For instance, in April 2022, Amlan International introduced two new natural alternatives to antibiotics for livestock and poultry: Phylox(R) Feed and NeutraPath(R). These products enhance intestinal health and improve production economics without using antibiotics. These new products offer enhanced intestinal health and production benefits, which may influence market dynamics by promoting natural solutions and potentially expanding options for livestock and poultry management.
The anticoccidial drugs industry is fragmented based on drug class, drug action, animal type, distribution channel, and region.
The coccidiocidal segment will see a considerable surge by 2032, attributed to its effectiveness in killing coccidia parasites and preventing the spread of coccidiosis. These drugs play a crucial role in managing and controlling infections in livestock, poultry, and other animals, which helps to maintain productivity and reduce economic losses. The high efficacy of coccidiocidal drugs in treating existing infections and preventing new outbreaks drives their dominance in the industry, as they are essential for ensuring animal health and optimizing agricultural output.
The livestock animals segment will garner remarkable gains by 2032 due to the critical need for effective disease management in animal agriculture. Anticoccidial drugs are essential for preventing and treating coccidiosis, a parasitic infection that affects livestock and can lead to major economic losses. As the demand for meat and dairy products rises, farmers and producers increasingly rely on these drugs to maintain animal health and productivity. The focus on improving livestock welfare and reducing disease outbreaks supports the segment's dominance.
Europe anticoccidial drugs market will secure a moderate CAGR through 2032, owing to its stringent regulatory standards, advanced veterinary practices, and high livestock production levels. The region's focus on maintaining rigorous animal health protocols and preventing disease outbreaks drives demand for effective anticoccidial solutions. Besides, Europe's commitment to integrating innovative treatments and ensuring high-quality animal care contributes to its substantial market share. This combination of regulatory support, industry standards, and technological progress makes Europe a notable contributor to the global anticoccidial drugs industry.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing incidence of coccidiosis
- 3.2.1.2 Growing livestock population
- 3.2.1.3 Rising demand for animal protein
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of drug development
- 3.2.2.2 Stringent regulatory requirements
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Synthetic compounds
- 5.3 Polyether antibiotics or ionophores
Chapter 6 Market Estimates and Forecast, By Drug Action, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Coccidiostatic
- 6.3 Coccidiocidal
Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Companion animals
- 7.2.1 Dogs
- 7.2.2 Cats
- 7.2.3 Other companion animals
- 7.3 Livestock animals
- 7.3.1 Cattle
- 7.3.2 Poultry
- 7.3.3 Other livestock animals
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Veterinary hospitals & pharmacies
- 8.3 Retail pharmacies
- 8.4 Other distribution channels
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Bayer AG
- 10.2 Boehringer Ingelheim International GmbH
- 10.3 Ceva
- 10.4 Cronus Pharma LLC
- 10.5 Elanco Animal Health Incorporated
- 10.6 Huvepharma EOOD
- 10.7 Impextraco NV
- 10.8 Merck & Co., Inc.
- 10.9 Phibro Animal Health Corporation
- 10.10 Vetoquinol SA
- 10.11 Virbac SA
- 10.12 Zoetis Inc.
